


We claim:

1. A method of treating hepatitis C in a mammal having symptoms of hepatitis C comprising administering to said mammal an effective amount of a pharmaceutical composition comprising a compound having the structure



and pharmaceutically acceptable salts thereof, wherein:

R₁, R₂, R₃, R₄ and R₅ are independently selected from the group consisting of hydrogen, halogen, methyl, ethyl, methoxy, nitro, C₂-C₄ alkenyl, cyano, and trifluoromethyl;

X is O, S, NH, or NR where R is a C₁-C₄ alkyl group;

W is CO₂H or 5- tetrazolyl;

Z is hydrogen or mono-methyl and

G is either OH, F, or hydrogen.

2. The method of claim 1 wherein the compound is selected from the group consisting of

- 2- {[(2,4-dichlorophenoxy)acetyl]amino } benzoic acid;
- 2- {[(2,5-dimethylphenoxy)acetyl]amino } benzoic acid;
- 2- {[(2-ethoxy-5-Z-(2-propenyl)phenoxy)acetyl]amino } benzoic acid;
- 2- {[(2-bromo-5-fluorophenoxy)acetyl]amino } benzoic acid;
- 2- {[(2-methyl-5-nitrophenoxy)acetyl]amino } benzoic acid;
- 2- {[(2-fluoro-5-methylphenoxy)acetyl]amino } benzoic acid;
- 2-[2-(4-Bromo-phenoxy)-acetylamino]-benzoic acid;
- 2-[2-(3-Bromo-phenoxy)-acetylamino]-benzoic acid;

2-[2-(2-Bromo-phenoxy)-acetylamino]-benzoic acid;
2-[2-(4-Bromo-phenoxy)-propionylamino]-benzoic acid;
2-[2-(4-Bromo-phenylsulfanyl)-acetylamino]-benzoic acid;
2-[2-(4-Chloro-phenoxy)-acetylamino]-benzoic acid;
2-[2-(4-Fluoro-phenoxy)-acetylamino]-benzoic acid;
2-{{(3-chlorophenoxy)acetyl}amino}benzoic acid;
2-{{(3-chlorophenoxy)acetyl}amino}-5-fluorobenzoic acid;
2-{{(3-chlorophenoxy)acetyl}amino}-5-hydroxybenzoic acid;
2-{{(3,4-dimethylphenoxy)acetyl}amino}-5-hydroxybenzoic acid;
2-{{(3-bromophenoxy)acetyl}amino}-5-hydroxybenzoic acid;
2-{{(2S)-2-(4-chlorophenoxy)propanoyl}amino}benzoic acid;
2-{{(2,3-dichlorophenoxy)acetyl}amino}-5-hydroxybenzoic acid;
2-{{(2,4,5-trichlorophenoxy)acetyl}amino}benzoic acid;
2-{{(2,4-dibromophenoxy)acetyl}amino}benzoic acid;
2-{{(2-chlorophenoxy)acetyl}amino}benzoic acid;
2-{{[N-(3-bromophenyl)glycyl]amino}benzoic acid;
2-{{[N-(4-bromo-3-chlorophenyl)-N-methylglycyl]amino}benzoic acid;
2-{{(4-chloro-2-methylphenoxy)acetyl}amino}benzoic acid;
2-{{(5-chloro-2-methylphenoxy)acetyl}amino}benzoic acid;
2-{{(3,4-difluorophenoxy)acetyl}amino}benzoic acid;
2-(4-chlorophenoxy)-N-[2-(1H-tetrazol-5-yl)phenyl]acetamide;
2-{{[N-(3,4-dibromophenyl)-N-methylglycyl]amino}benzoic acid;
2-{{[N-(2,5-dibromophenyl)glycyl]amino}benzoic acid;
2-{{(2-cyanophenoxy)acetyl}amino}benzoic acid;
5-hydroxy-2-{{(2,4,5-trichlorophenoxy)acetyl}amino}benzoic acid;
2-{{(2-chloro-4,5-dimethylphenoxy)acetyl}amino}benzoic acid;
2-{{(4-chloro-3-(trifluoromethyl)phenoxy)acetyl}amino}benzoic acid;
2-{{(2-bromo-4-chloro-5-methylphenoxy)acetyl}amino}benzoic acid;
2-{{(2-ethyl-4,5-dimethylphenoxy)acetyl}amino}benzoic acid;


2-({[(3,4-dichlorophenyl)sulfanyl]acetyl}amino)benzoic acid;
2-({[(4-chlorophenyl)sulfanyl]acetyl}amino)benzoic acid;
2-({[(2-bromo-4,5-difluorophenoxy)acetyl]amino}benzoic acid;
2-({[3-(trifluoromethyl)phenoxy]acetyl}amino)benzoic acid;
2-({[(2-bromo-4-chloro-5-methylphenoxy)acetyl]amino}-5-hydroxybenzoic
acid;
2-({[(2,4,5-trifluorophenoxy)acetyl]amino}benzoic acid;
2-({[(3,5-dichlorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;
2-({[(2,4,5-trichlorophenyl)thio]acetyl}amino)benzoic acid;
2-({[N-(3,4-dichlorophenyl)-N-methylglycyl]amino}benzoic acid;
2-({[(3,5-difluorophenoxy)acetyl]amino}benzoic acid;
2-({[(3,5-difluorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;
2-({[(2-bromophenoxy)acetyl]amino}-5-hydroxybenzoic acid;
2-({[(2-chloro-6-methylphenoxy)acetyl]amino}benzoic acid;
2-({[(4-chloro-3-ethylphenoxy)acetyl]amino}benzoic acid;
2-({[N-(2,4,5-trichlorophenyl)glycyl]amino}benzoic acid;
5-hydroxy-2-({[N-(2,4,5-trichlorophenyl)glycyl]amino}benzoic acid;
2-({[(3-chloro-4-methylphenoxy)acetyl]amino}benzoic acid;
2-({[(3-chloro-4-methylphenoxy)acetyl]amino}-5-hydroxybenzoic acid;
2-({[(2-chloro-5-fluorophenoxy)acetyl]amino}benzoic acid;
2-({[(2-chloro-5-fluorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;
2-({[(3-chloro-4-fluorophenoxy)acetyl]amino}benzoic acid;
2-({[(3-chloro-4-fluorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;
2-({[(4-chloro-3-fluorophenoxy)acetyl]amino}benzoic acid;
2-({[N-(3,4-difluorophenyl)glycyl]amino}benzoic acid;
2-({[N-(3,4-dichlorophenyl)glycyl]amino}benzoic acid;
2-({[N-(2,5-dibromophenyl)glycyl]amino}-5-hydroxybenzoic acid;
2-({[N-(4-chloro-2-fluorophenyl)glycyl]amino}benzoic acid;
2-({[(4-chloro-3-fluorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2- {[N-(2-fluoro-4-methylphenyl)glycyl]amino} benzoic acid;
2- {[N-(3,4-dichlorophenyl)glycyl]amino}-5-hydroxybenzoic acid;
2- {[N-(2,5-dichlorophenyl)glycyl]amino} benzoic acid;
2- {[N-(2,5-dichlorophenyl)glycyl]amino}-5-hydroxybenzoic acid;
2- {[N-(3,4-dichlorophenyl)-N-ethylglycyl]amino} benzoic acid;
2- {[N-(3,4-dichlorophenyl)-N-ethylglycyl]amino}-5-hydroxybenzoic acid;
2- {[N-(3,4-dichlorophenyl)-N-propylglycyl]amino} benzoic acid;
2- {[N-(3,4-dichlorophenyl)-N-propylglycyl]amino}-5-hydroxybenzoic acid;
2- {[N-(2,5-dichlorophenyl)-N-methylglycyl]amino}-5-hydroxybenzoic
acid;
2- {[N-(3,4-dichlorophenyl)-N-methylglycyl]amino}-5-hydroxybenzoic
acid;
2- {[N-(3-chloro-4-fluorophenyl)glycyl]amino} benzoic acid;
2- {[N-(3,4-dimethylphenoxy)acetyl]amino}-5-hydroxybenzoic acid;
2- {[N-(2-chlorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;
2- {[N-(2-bromo-4-methylphenoxy)acetyl]amino} benzoic acid;
2- {[N-(4-nitrophenoxy)acetyl]amino}-5-hydroxybenzoic acid;
2- {[N-(2-(2-chloro-phenoxy)acetyl]amino} benzoic acid;
2- {[N-(4-bromophenyl)methyl] [2-isopropyl-5-
methylphenoxyacetyl]amino} benzoic acid;
2- {[N-(4-cyclohexylphenoxy)acetyl]amino} benzoic acid; and
pharmaceutically acceptable salts thereof.

3. The method of claim 1 wherein the compound is selected from the group consisting of

2- {[N-(2,4,5-trichlorophenoxy)acetyl]amino} benzoic acid;
2- {[N-(2,5-dibromophenyl)glycyl]amino}-5-hydroxybenzoic acid;
2- {[N-(3,4-dichlorophenyl)glycyl]amino}-5-hydroxybenzoic acid; and
pharmaceutically acceptable salts thereof.

4. The method of claim 1 wherein the compound is selected from the group consisting of
5-hydroxy-2-[[(2,4,5-trichlorophenoxy)acetyl]amino]benzoic acid;
2-[[(2-bromo-4-chloro-5-methylphenoxy)acetyl]amino]-5-hydroxybenzoic acid;
2-[[N-(3,4-dichlorophenyl)-N-methylglycyl]amino]-5-hydroxybenzoic acid; and pharmaceutically acceptable salts thereof.
5. The method of claim 1 wherein the mammal is human.
6. The method of claim 5 wherein the composition is administered orally to said human.
7. The method of claim 6 wherein the compound is administered orally at a dose range of about 0.01 to 100 mg/kg from 1 to 6 times a day.
8. The method of claim 7 wherein the compound is administered orally at a dose range of about 0.1 to 10 mg/kg from 1 to 6 times a day.
9. The method of claim 8 wherein the compound is administered from 1 to 4 times a day.
10. The method of claim 5 wherein the composition is administered subcutaneously to said human.
11. A pharmaceutical composition for the treatment of hepatitis comprising a compound having the structure



and pharmaceutically acceptable salts thereof, wherein:

R₁, R₂, R₃, R₄ and R₅ are independently selected from the group consisting of hydrogen, halogen, methyl, ethyl, methoxy, nitro, C₂-C₄ alkenyl, cyano, and trifluoromethyl;

X is O, S, NH, or NR where R is a C₁-C₄ alkyl group;

W is CO₂H or 5-tertrazolyl;

Z is hydrogen or mono-methyl and

G is either OH, F, or hydrogen.

12. The composition of claim 11 wherein the compound is selected from the group consisting of

- 2-{[(2,4-dichlorophenoxy)acetyl]amino}benzoic acid;
- 2-{[(2,5-dimethylphenoxy)acetyl]amino}benzoic acid;
- 2-{[(2-ethoxy-5-Z-(2-propenyl)phenoxy)acetyl]amino}benzoic acid;
- 2-{[(2-bromo-5-fluorophenoxy)acetyl]amino}benzoic acid;
- 2-{[(2-methyl-5-nitrophenoxy)acetyl]amino}benzoic acid;
- 2-{[(2-fluoro-5-methylphenoxy)acetyl]amino}benzoic acid;
- 2-[2-(4-Bromo-phenoxy)-acetylamino]-benzoic acid;
- 2-[2-(3-Bromo-phenoxy)-acetylamino]-benzoic acid;
- 2-[2-(2-Bromo-phenoxy)-acetylamino]-benzoic acid;
- 2-[2-(4-Bromo-phenoxy)-propionylamino]-benzoic acid;
- 2-[2-(4-Bromo-phenylsulfanyl)-acetylamino]-benzoic acid;
- 2-[2-(4-Chloro-phenoxy)-acetylamino]-benzoic acid;

2-[2-(4-Fluoro-phenoxy)-acetylamino]-benzoic acid;
2-{{(3-chlorophenoxy)acetyl}amino}benzoic acid;
2-{{(3-chlorophenoxy)acetyl}amino}-5-fluorobenzoic acid;
2-{{(3-chlorophenoxy)acetyl}amino}-5-hydroxybenzoic acid;
2-{{(3,4-dimethylphenoxy)acetyl}amino}-5-hydroxybenzoic acid;
2-{{(3-bromophenoxy)acetyl}amino}-5-hydroxybenzoic acid;
2-{{(2S)-2-(4-chlorophenoxy)propanoyl}amino}benzoic acid;
2-{{(2,3-dichlorophenoxy)acetyl}amino}-5-hydroxybenzoic acid;
2-{{(2,4,5-trichlorophenoxy)acetyl}amino}benzoic acid;
2-{{(2,4-dibromophenoxy)acetyl}amino}benzoic acid;
2-{{(2-chlorophenoxy)acetyl}amino}benzoic acid;
2-{{[N-(3-bromophenyl)glycyl]amino}benzoic acid;
2-{{[N-(4-bromo-3-chlorophenyl)-N-methylglycyl]amino}benzoic acid;
2-{{(4-chloro-2-methylphenoxy)acetyl}amino}benzoic acid;
2-{{(5-chloro-2-methylphenoxy)acetyl}amino}benzoic acid;
2-{{(3,4-difluorophenoxy)acetyl}amino}benzoic acid;
2-(4-chlorophenoxy)-N-[2-(1H-tetrazol-5-yl)phenyl]acetamide;
2-{{[N-(3,4-dibromophenyl)-N-methylglycyl]amino}benzoic acid;
2-{{[N-(2,5-dibromophenyl)glycyl]amino}benzoic acid;
2-{{(2-cyanophenoxy)acetyl}amino}benzoic acid;
5-hydroxy-2-{{(2,4,5-trichlorophenoxy)acetyl}amino}benzoic acid;
2-{{(2-chloro-4,5-dimethylphenoxy)acetyl}amino}benzoic acid;
2-{{[4-chloro-3-(trifluoromethyl)phenoxy]acetyl}amino}benzoic acid;
2-{{(2-bromo-4-chloro-5-methylphenoxy)acetyl}amino}benzoic acid;
2-{{(2-ethyl-4,5-dimethylphenoxy)acetyl}amino}benzoic acid;
2-{{(3,4-dichlorophenyl)sulfanyl}acetyl}amino}benzoic acid;
2-{{(4-chlorophenyl)sulfanyl}acetyl}amino}benzoic acid;
2-{{(2-bromo-4,5-difluorophenoxy)acetyl}amino}benzoic acid;
2-{{[3-(trifluoromethyl)phenoxy]acetyl}amino}benzoic acid;

2- {[(2-bromo-4-chloro-5-methylphenoxy)acetyl]amino }-5-hydroxybenzoic acid;

2- {[(2,4,5-trifluorophenoxy)acetyl]amino }benzoic acid;

2- {[(3,5-dichlorophenoxy)acetyl]amino }-5-hydroxybenzoic acid;

2- ({[(2,4,5-trichlorophenyl)thio]acetyl }amino)benzoic acid;

2- {[N-(3,4-dichlorophenyl)-N-methylglycyl]amino }benzoic acid;

2- {[(3,5-difluorophenoxy)acetyl]amino }benzoic acid;

2- {[(3,5-difluorophenoxy)acetyl]amino }-5-hydroxybenzoic acid;

2- {[(2-bromophenoxy)acetyl]amino }-5-hydroxybenzoic acid;

2- {[(2-chloro-6-methylphenoxy)acetyl]amino }benzoic acid;

2- {[(4-chloro-3-ethylphenoxy)acetyl]amino }benzoic acid;

2- {[N-(2,4,5-trichlorophenyl)glycyl]amino }benzoic acid;

5-hydroxy-2- {[N-(2,4,5-trichlorophenyl)glycyl]amino }benzoic acid;

2- {[(3-chloro-4-methylphenoxy)acetyl]amino }benzoic acid;

2- {[(3-chloro-4-methylphenoxy)acetyl]amino }-5-hydroxybenzoic acid;

2- {[(2-chloro-5-fluorophenoxy)acetyl]amino }benzoic acid;

2- {[(2-chloro-5-fluorophenoxy)acetyl]amino }-5-hydroxybenzoic acid;

2- {[(3-chloro-4-fluorophenoxy)acetyl]amino }benzoic acid;

2- {[(3-chloro-4-fluorophenoxy)acetyl]amino }-5-hydroxybenzoic acid;

2- {[(4-chloro-3-fluorophenoxy)acetyl]amino }benzoic acid;

2- {[N-(3,4-difluorophenyl)glycyl]amino }benzoic acid;

2- {[N-(3,4-dichlorophenyl)glycyl]amino }benzoic acid;

2- {[N-(2,5-dibromophenyl)glycyl]amino }-5-hydroxybenzoic acid;

2- {[N-(4-chloro-2-fluorophenyl)glycyl]amino }benzoic acid;

2- {[(4-chloro-3-fluorophenoxy)acetyl]amino }-5-hydroxybenzoic acid;

2- {[N-(2-fluoro-4-methylphenyl)glycyl]amino }benzoic acid;

2- {[N-(3,4-dichlorophenyl)glycyl]amino }-5-hydroxybenzoic acid;

2- {[N-(2,5-dichlorophenyl)glycyl]amino }benzoic acid;

2- {[N-(2,5-dichlorophenyl)glycyl]amino }-5-hydroxybenzoic acid;

2- {[N-(3,4-dichlorophenyl)-N-ethylglycyl]amino} benzoic acid;
2- {[N-(3,4-dichlorophenyl)-N-ethylglycyl]amino}-5-hydroxybenzoic acid;
2- {[N-(3,4-dichlorophenyl)-N-propylglycyl]amino} benzoic acid;
2- {[N-(3,4-dichlorophenyl)-N-propylglycyl]amino}-5-hydroxybenzoic acid;
2- {[N-(2,5-dichlorophenyl)-N-methylglycyl]amino}-5-hydroxybenzoic
acid;
2- {[N-(3,4-dichlorophenyl)-N-methylglycyl]amino}-5-hydroxybenzoic
acid;
2- {[N-(3-chloro-4-fluorophenyl)glycyl]amino} benzoic acid;
2- {[(3,4-dimethylphenoxy)acetyl]amino}-5-hydroxybenzoic acid;
2- {[(2-chlorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;
2- {[(2-bromo-4-methylphenoxy)acetyl]amino} benzoic acid;
2- {[(4-nitrophenoxy)acetyl]amino}-5-hydroxybenzoic acid;
2- {[2-(2-chloro-phenoxy)acetyl]amino} benzoic acid;
2- {[(4-bromophenyl)methyl} {2-isopropyl-5-
methylphenoxyacetyl]amino} benzoic acid;
2- {[(4-cyclohexylphenoxy)acetyl]amino} benzoic acid, and
pharmaceutically acceptable salts thereof.

13. The composition of claim 11 wherein the compound is selected from the group consisting of

2- {[(2,4,5-trichlorophenoxy)acetyl]amino} benzoic acid;
2- {[N-(2,5-dibromophenyl)glycyl]amino}-5-hydroxybenzoic acid;
2- {[N-(3,4-dichlorophenyl)glycyl]amino}-5-hydroxybenzoic acid; and
pharmaceutically acceptable salts thereof.


14. The composition of claim 11 wherein the compound is selected from the group consisting of

5-hydroxy-2- {[(2,4,5-trichlorophenoxy)acetyl]amino} benzoic acid;

2- {[(2-bromo-4-chloro-5-methylphenoxy)acetyl]amino }-5-hydroxybenzoic acid;

2- {[N-(3,4-dichlorophenyl)-N-methylglycyl]amino }-5-hydroxybenzoic acid; and pharmaceutically acceptable salts thereof.

15. A method of treating hepatitis C in a mammal having symptoms of hepatitis C comprising administering to said mammal an effective amount of a pharmaceutical composition comprising a compound having the structure



and pharmaceutically acceptable salts thereof, wherein:

R₁, R₂, R₃, R₄ and R₅ are independently selected from the group consisting of hydrogen, halogen, methyl, ethyl, methoxy, nitro, C₂-C₄ alkenyl, cyano, and trifluoromethyl;

X is O, S, NH, or NR where R is a C₁-C₄ alkyl group;

Y is CO₂H or CO₂CH₃;

Z is hydrogen or mono-methyl;

G₁ is OH, F, methoxy or hydrogen; and


G₂ is either OH, Cl, methoxy or hydrogen.

16. The method of claim 15 wherein the compound is selected from the group consisting of

2-[(4-chlorophenoxy)acetylamino]-benzoic acid methyl ester;

2-[(4-methoxyphenoxy)acetylamino]-benzoic acid methyl ester;
2-[(4-cyclohexylphenoxy)acetylamino]-4,5-dimethoxybenzoic acid;
2-[(2-phenoxy)propionylamino]-4-hydroxybenzoic acid;
2-{[(3,4-dimethylphenoxy)acetyl]amino}-4-hydroxybenzoic acid;
2-[(3-methylphenoxy)acetylamino]-4,5-dimethoxybenzoic acid;
2-[(3-methylphenoxy)acetylamino]-4-chlorobenzoic acid; and
pharmaceutically acceptable salts thereof.

17. A pharmaceutical composition for the treatment of hepatitis comprising a compound having the structure



(II)

and pharmaceutically acceptable salts thereof, wherein:

R₁, R₂, R₃, R₄ and R₅ are independently selected from the group consisting of hydrogen, halogen, methyl, ethyl, methoxy, nitro, C₂-C₄ alkenyl, cyano, and trifluoromethyl;

X is O, S, NH, or NR where R is a C₁-C₄ alkyl group;

Y is CO₂H or CO₂CH₃;

Z is hydrogen or mono-methyl;

G₁ is OH, F, methoxy or hydrogen; and

G₂ is either OH, Cl, methoxy or hydrogen.

18. The method of claim 17 wherein the compound is selected from the group

consisting of

- 2-[(4-chlorophenoxy)acetylamino]-benzoic acid methyl ester;
- 2-[(4-methoxyphenoxy)acetylamino]-benzoic acid methyl ester;
- 2-[(4-cyclohexylphenoxy)acetylamino]-4,5-dimethoxybenzoic acid;
- 2-[(2-phenoxy)propionylamino]-4-hydroxybenzoic acid;
- 2- {[(3,4,-dimethylphenoxy)acetyl]amino} -4-hydroxybenzoic acid;
- 2-[(3-methylphenoxy)acetylamino]-4,5-dimethoxybenzoic acid;
- 2-[(3-methylphenoxy)acetylamino]-4-chlorobenzoic acid; and

pharmaceutically acceptable salts thereof.